Skip to main content

Table 1 Baseline clinical profile of the entire cohort

From: Blood consumption in total arterial coronary artery bypass grafting

VariableEntire cohort
N = 595
Total arterial CABG
N = 419 (70.4%)
Mixed CABG
N = 176 (29.6%)
p value
Male501 (84.2%)360 (85.9%)141 (80.1%)0.08
Age (y)66.1 ± 9.566.0 ± 9.566.5 ± 9.50.55
  < 60139 (23.4%)100 (23.9%)39 (22.2%)
 60–69230 (38.7%)167 (39.9%)63 (35.8%)
 70–79186 (31.3%)124 (29.6%)62 (35.2%)
  ≥ 8040 (6.7%)28 (6.7%)12 (6.8%)
Diabetes162 (27.2%)105 (25.1%)57 (32.4%)0.016
Hypertension427 (71.8%)299 (71.4%)128 (72.7%)0.07
Obesity (BMI > 30 kg/cm2)197 (33.1%)139 (33.2%)58 (32.9%)0.58
Dyslipidemia385 (64.7%)275 (65.6%)110 (62.5%)0.67
Preoperative hemoglobin13.2 ± 1.813.3 ± 1.713.0 ± 1.80.07
Preoperative LVEF52.0 ± 13.154.5 ± 11.845.7 ± 14.2< 0.001
Anticoagulation and antiaggregation
 No anticoagulation or antiaggregation48 (8.1%)36 (8.6%)12 (6.8%)0.60
 Acetylsalicylic acid498 (83.7%)359 (85.7%)139 (79.0%)0.61
 ADP receptor inhibitors121 (20.3%)87 (20.8%)34 (19.3%)0.96
 Vitamin K antagonists9 (1.5%)5 (1.2%)4 (2.3%)0.28
 Factor Xa inhibitors12 (2.0%)6 (1.4%)6 (3.4%)0.09
 GPIIb/IIIa inhibitors26 (4.4%)19 (4.5%)7 (4.0%)0.87
No. of distal anastomoses3.4 ± 1.03.1 ± 0.93.9 ± 0.9< 0.001
 2127 (21.3%)117 (27.9%)10 (5.7%)
 3221 (37.1%)170 (40.6%)51 (29.0%)
 4168 (28.2%)96 (22.9%)72 (40.9%)
 570 (11.8%)34 (8.1%)36 (20.5%)
 69 (1.5%)2 (0.5%)7 (4.0%)
Crossclamp time (min)78.2 ± 27.879.0 ± 28.976.2 ± 25.20.25
Composite grafting208 (35.0%)200 (47.7%)8 (4.5%)< 0.001
  1. LVEF left ventricular ejection fraction